Articles On Imugene (ASX:IMU)

Healthcare stocks are doing relatively well globally in 2024
 The sector could see more recovery as Fed cuts rates
 How ASX biotechs performed in the month of September   The S&P 500 Health Care Index, a key world benchmark for health...

Highlights Orphan Drug Designation (ODD) has been secured from the US FDA for VAXINIA (CF33-hNIS). Benefits of ODD include grant funding, tax credits, fee waivers, and seven years of market exclusivity following FDA approval. The MAST...

Imugene has landed a prized FDA orphan drug approval for its bile tract cancer therapy following positive results from its recent metastatic advanced solid tumour trials to treat the rare and insidious disease.

Appen Ltd (ASX: APX) shares have been on a meteoric rise, surging 260% higher in just seven weeks. Shares in the language technology data company were swapping hands at 43 cents per share on July 29, their lowest point in months. At...

The Appen Ltd (ASX: APX) share price is off to the races today. Shares in the All Ordinaries Index (ASX: XAO) AI stock closed yesterday trading for $1.29. In afternoon trade on Thursday, shares are swapping hands for $1.52 apiece, up 18...

DroneShield Ltd (ASX: DRO) shares are rebounding on Wednesday morning after a 7% decline yesterday. In morning trade, the counterdrone technology company's shares are up 7% to $1.33. This compares favourably to the 0.1% gain by the benchmar...

DroneShield Ltd (ASX: DRO) shares have been a top performer this year, soaring 236% into the green to fetch $1.24 at Tuesday's close. The giant leap in market value is underpinned by equally strong growth in DroneShield's underlying busi...

In early afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is back on form and pushing higher. At the time of writing, the benchmark index is up 0.3% to 7,975.3 points. Four ASX shares that are rising more than most today are listed bel...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to record a very disappointing decline. At the time of writing, the benchmark index is down 1.8% to 7,956.8 points. Four ASX shares that are not letting that hold them ba...

S&P/ASX All Ordinaries Index (ASX: XAO) stock Cettire Ltd (ASX: CTT) has gained momentum recently and climbed 18% in the past month of trade. Today, the luxury online retailer posted an announcement advising that its Founder and CEO,...

ASX health stocks down in August and trail the broader market in 2024 CSL up 6,000pc since listing; sector outpaced benchmark 10x since 2006 AI is revolutionising healthcare, boosting diagnosis and treatment   The ASX Healthcare Index (AS...

S&P/ASX All Ords (ASX: XAO) shares essentially moved sideways in August, losing just 0.04%. However, this belies the volatility we saw last month as stocks lurched back and forth on earnings reports. As is typical during earnin...

The first two blood cancer patients in a US-based trial, who had suffered relapses despite having treatment, have now been in remission for up to 120 days after being dosed with Imugene’s azer-cel therapy.

The ASX200 has closed up 0.22% at 8110 after shaking off early losses. Sectors were a hodgepodge with Financials the best performer, up 1.15%, followed closely by Energy 1.1%. Materials was the worst performer, down around 1.1% and Telec...

The Australian sharemarket made notable strides on Monday, approaching its record closing high, thanks to robust performances from major banks and energy stocks, despite pressures from the mining sector. The S&P/ASX 200 Index edged 0.2%...

The ASX ended higher after a slow start Energy stocks leading while telcos and miners lagged Asian stocks mostly declined amid ongoing economic weakness    After a sluggish start, the ASX ended Monday higher by 0.22% as September trading...

In the first session of the week, the Australian sharemarket is experiencing a steady performance, with major banks and miners exerting opposing influences on the S&P/ASX 200 index. As trading enters its final hours, the index remains r...

In the first trading session of the week, the Australian sharemarket is experiencing a downward trend, primarily influenced by movements in the mining and communications sectors.  As of midday, the S&P/ASX 200 Index (ASX: XJO) is down...

With so many shares to choose from on the Australian share market, it can be difficult to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you. Three top ASX shares that leading...

The ASX200 has been up down 0.12% at 8,082 points, even on the back of Wall Street chalking up solid gains on Friday. Australian second quarter GDP growth figures are out this Wednesday and the consensus forecast is a further slowing in...

  Imugene (ASX:IMU) announced promising results from its Phase 1b clinical trial with azer-cel, in patients with relapsed/refractory diffuse large B cell lymphoma. All enrolled patients had cancer that had returned following autologous CAR...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to start the week with a decline. At the time of writing, the benchmark index is down 0.2% to 8,074.4 points. Four ASX shares that are not letting that hold them back ar...

The DroneShield Ltd (ASX: DRO) share price is leaping higher today despite the broader stock market selling action. Shares in the All Ordinaries Index (ASX: XAO) drone defence company closed on Friday trading for $1.33. In early afterno...

Imugene Ltd (ASX: IMU) shares are starting the week with a bang. In morning trade, the ASX All Ords stock is up 30% to 8.1 cents. Why is this ASX All Ords stock rocketing? Investors have been fighting to get hold of the clinical stage immun...

Imugene’s stock surges on promising Phase 1b results Emyria’s MDMA therapy for PTSD shows quality of life improvements Both companies are expanding their programs and advancing towards further trials   Imugene reports advances in Azer-Cel...

Highlights Ten patients were enrolled in the Phase 1b trial of azer-cel, divided into two cohorts: Cohort A (azer-cel and lymphodepletion) and Cohort B (azer-cel, lymphodepletion, and IL-2). Three patients (two from Cohort B, one from...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

Imugene (ASX: IMU) has announced positive results from a Phase 1b clinical trial using lead candidate azer-cel on patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Ten enrolled patients had previously undergone up...

Imugene (ASX:IMU) has announced 3 patients in its latest blood cancer treatment trial using azer-cel have responded well with one showing a complete response for over 100 days. A ‘complete response’ in this case is a complete disappeara...

Cettire Ltd (ASX: CTT) shares were hammered last week. Investors were hitting the sell button after the ASX tech share released its disappointing full year results. The online luxury products retailer reported an 81% increase in gross reven...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin By Tim Boreham ASX code: ((ALA)) Shares on issue: 1,050,775,660 Market cap: $157.6m...

This article is part of the daily news updates from FNArena.com. Stay informed with the latest financial, business, and economic insights. Written by Admin World Overnight SPI Overnight 7948.00 – 43.00 – 0.54% S&P ASX 200 8027.00...

Highlights Imugene ended the June quarter with over AU$93 million in cash and equivalents, supporting operations through late 2025. The company is actively recruiting for three Phase 1/1b clinical trials across multiple countries. The...

S&P/ASX 200 Health Care index up 5pc in July, 9.5pc YTD Health sector gains momentum with expected Fed rate cuts; ResMed seen as a strong buy And ASX healthcare winners and losers in July   The S&P/ASX 200 Health Care index [XHJ]...

The EMA has rejected the Alzheimer’s drug Leqembi, developed by Eisai and Biogen There is one ASX-listed company that collaborates with Eisai We take a look at the best performing ASX health stocks in the past month   In a major blow for...

The S&P/ASX 200 Index (ASX: XJO) is up 2.5% and in new all-time high territory as we near the end of the second trading week of FY 2025. But some ASX shares have already done much better. Now, two weeks is only a small snapshot for thes...

If you're building an income portfolio, then it could be worth looking at the ASX 200 dividend stocks named below. Here's why they could be good options for income investors this month: Cedar Woods Properties Limited (ASX: CWP) Morgans th...

There's an ASX dividend stock on the market right now that, until very recently, was yielding close to 5%. This particular ASX 200 blue chip has rallied significantly over the past few weeks, which has now pushed down its dividend yield clo...

Telstra Group Ltd (ASX: TLS) stock is regularly viewed as an appealing ASX dividend share to own. This could be a compelling time to consider the company for its passive income and dividend potential. Businesses that are able to deliver...

It was a sobering Wednesday session for the S&P/ASX 200 Index (ASX: XJO) and many ASX shares today. After recording a strong gain yesterday, investors appear to hav...

Imugene has dosed its first of 10 Australian patients with its potent “VAXINIA” therapy as part of its phase-one bile tract cancer trial being conducted at St Vincent’s Hospital in Melbourne.

The S&P 500 Index (SP: .INX) and Nasdaq Composite Index (NASDAQ: .IXIC) reached new all-time highs on Wall Street last night. It should be a cause for celebration. If only the record weren't accompanied by a more sinister number crack...

The market is having a bit of a subdued session on Wednesday, but that isn't stopping one ASX robotics stock from storming higher again. At the time of writing, the FBR Ltd (ASX: FBR) share price is up 19% to 5.6 cents. This means that its...

The ASX is down 0.3% to 7,807 points heading into lunchtime trade. Telecommunications is the only sector in the green up 0.9%. This is on the back of Telstra’s pricing announcement released yesterday. All other sectors are in the red wit...

Highlights The first patient in the Phase 1 bile tract cancer trial has been dosed. The trial is expected to enrol 10 patients with bile tract cancer. The sixth high dose cohort of both arms of the Phase 1 MAST monotherapy dose escala...

The market may have run out of steam on Wednesday, but not all ASX shares are falling. Two that are catching the eye of investors and roaring higher this morning are listed below. Here's why investors have been buying their shares today: D...

The ASX Health Care index saw a 4% increase in June Growth was driven by CSL and Cochlear Best biotechs in June were Actinogen, Optiscan and EZZ Life Science, amongst others    The S&P/ASX 200 Health Care index [XHJ] saw a 4% increase...

Imugene has confirmed the delivery of its first “onCARlytics” combination therapy dose to a bile duct cancer patient in the initial phase of a world-first trial at the City of Hope medical centre in the US.

Highlights The first patient has received treatment under the intravenous (IV) infusion combination arm of the Phase 1 onCARlytics trial. The trial aims to enrol nearly 40-45 patients with advanced solid cancers that have spread. Prel...

Imugene Limited (ASX: IMU), has dosed the first patient in the phase 1 clinical trial known as OASIS, which is testing its oncolytic virotherapy drug. The clinical trial is targeting adult patients with advanced or metastatic solid tumou...